Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-ggqkh Total loading time: 0 Render date: 2025-05-05T18:22:41.113Z Has data issue: false hasContentIssue false

16 - Dementia treatment

Published online by Cambridge University Press:  31 July 2009

By
Bradley F. Boeve  and
Adam L. Boxer
Edited by
Bruce L. Miller  and
Bradley F. Boeve
Bruce L. Miller
Affiliation:
University of California, San Francisco
Bradley F. Boeve
Affiliation:
Mayo Foundation, Minnesota
Get access

Summary

Introduction

There is reason for optimism about future treatment of the most common causes of dementia. Advances in understanding the molecular pathologies that underlie the most common causes of neurodegenerative dementia are rapidly being translated into new treatments. At the same time, basic investigations into the neurophysiology of synaptic transmission, neuronal growth, development and survival have identified new receptors, genes and intracellular second messenger cascades that may serve as targets for new treatments for dementia. Whereas most currently approved medications that are used to treat dementia are effective only in ameliorating the symptoms of disease, in the near future, medications that modify the course of the disease by protecting the brain from dementia-related pathology may be available. New diagnostic tests will also help to identify accurately who is likely to benefit from such treatment and monitor their treatment response. This chapter will review the currently available treatments for the most common forms of dementia, focusing on clinical syndromes that are readily identifiable by practicing clinicians, as well as new treatments that are currently under investigation or new avenues for treatment suggested by recent advances in understanding the molecular pathologies of these disorders.

Type
Chapter
Information
The Behavioral Neurology of Dementia , pp. 213 - 253
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

McKeith, IG, Dickson, DW, Lowe, Jet al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–1872.CrossRefGoogle ScholarPubMed
Rowe, CC, Ng, S, Ackermann, Uet al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718–1725.CrossRefGoogle ScholarPubMed
Neumann, M, Mackenzie, IR, Cairns, NJet al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007;66:152–157.CrossRefGoogle ScholarPubMed
Johnson, KA. Amyloid imaging of Alzheimer's disease using Pittsburgh Compound B. Curr Neurol Neurosci Rep. 2006;6:496–503.CrossRefGoogle ScholarPubMed
Small, GW, Kepe, V, Ercoli, LMet al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–2663.CrossRefGoogle ScholarPubMed
Mintun, MA, Larossa, GN, Sheline, YIet al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446–452.CrossRefGoogle Scholar
Kemppainen, NM, Aalto, S, Wilson, IAet al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68:1603–1606.CrossRefGoogle ScholarPubMed
Hye, A, Lynham, S, Thambisetty, Met al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006;129:3042–3050.CrossRefGoogle ScholarPubMed
Simonsen, AH, McGuire, J, Hansson, Oet al. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol. 2007;64:366–370.CrossRefGoogle ScholarPubMed
Finehout, EJ, Franck, Z, Choe, LHet al. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol. 2007;61:120–129.CrossRefGoogle ScholarPubMed
Weiner, HL, Frenkel, D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol. 2006;6:404–416.CrossRefGoogle ScholarPubMed
Bayer, AJ, Bullock, R, Jones, RWet al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64:94–101.CrossRefGoogle ScholarPubMed
Lee, M, Bard, F, Johnson-Wood, Ket al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol. 2005;58:430–435.CrossRefGoogle ScholarPubMed
Fox, NC, Black, RS, Gilman, Set al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563–1572.CrossRefGoogle ScholarPubMed
Gilman, S, Koller, M, Black, RSet al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–1562.CrossRefGoogle Scholar
Aisen, PS, Saumier, D, Briand, Ret al. A Phase II study targeting amyloid-beta with 3APS in mild to moderate Alzheimer disease. Neurology. 2006;67:1757–1763.CrossRefGoogle ScholarPubMed
Siemers, ER, Quinn, JF, Kaye, Jet al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602–604.CrossRefGoogle Scholar
Eriksen, JL, Sagi, SA, Smith, TEet al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003;112:440–449.CrossRefGoogle ScholarPubMed
Petersen, RC, Parisi, JE, Dickson, DWet al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63:665–672.CrossRefGoogle ScholarPubMed
Graham, A, Davies, R, Xuereb, Jet al. Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain. 2005;128:597–605.CrossRefGoogle ScholarPubMed
Petersen, RC, Thomas, RG, Grundman, Met al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–2388.CrossRefGoogle ScholarPubMed
Feldman, HH, Ferris, S, Winblad, Bet al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6:501–512.CrossRefGoogle ScholarPubMed
Caselli, RJ, Windebank, AJ, Petersen, RCet al. Rapidly progressive aphasic dementia and motor neuron disease. Ann Neurol. 1993;33:200–207.CrossRefGoogle ScholarPubMed
Tang-Wai, DF, Graff-Radford, NR, Boeve, BFet al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63:1168–1174.CrossRefGoogle ScholarPubMed
Renner, JA, Burns, JM, Hou, CEet al. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology. 2004;63:1175–1180.CrossRefGoogle ScholarPubMed
Caselli, R. Focal and asymmetric cortical degeneration syndromes. Neurologist. 1995;1:1–19.Google Scholar
Caselli, RJ. Asymmetric cortical degeneration syndromes. Curr Opin Neurol. 1996;9:276–280.CrossRefGoogle ScholarPubMed
Benson, DF, Davis, RJ, Snyder, BD. Posterior cortical atrophy. Arch Neurol. 1988;45:789–793.CrossRefGoogle ScholarPubMed
Tang-Wai, DF, Josephs, KA, Boeve, BFet al. Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction. Neurology. 2003;61:1134–1135.CrossRefGoogle ScholarPubMed
Furuya, H, Ikezoe, K, Ohyagi, Yet al. A case of progressive posterior cortical atrophy (PCA) with vivid hallucination: are some ghost tales vivid hallucinations in normal people?J Neurol Neurosurg Psychiatry. 2006;77:424–425.CrossRefGoogle ScholarPubMed
Josephs, KA, Whitwell, JL, Boeve, BFet al. Visual hallucinations in posterior cortical atrophy. Arch Neurol. 2006;63:1427–1432.CrossRefGoogle ScholarPubMed
Wolf, RC, Schonfeldt-Lecuona, C. Depressive symptoms as first manifestation of posterior cortical atrophy. Am J Psychiatry. 2006;163:939–940.CrossRefGoogle ScholarPubMed
Mendez, MF, Ghajarania, M, Perryman, KM. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14:33–40.CrossRefGoogle ScholarPubMed
McKeith, IG, Galasko, D, Kosaka, Ket al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB International Workshop. Neurology. 1996;47:1113–1124.CrossRefGoogle Scholar
Grace, J, McKeith, IG. Decline in cognitive function in Parkinson's disease may be due to dementia with Lewy bodies. BMJ. 1998;316:1022.CrossRefGoogle ScholarPubMed
Apaydin, H, Ahlskog, JE, Parisi, JEet al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol. 2002;59:102–112.CrossRefGoogle ScholarPubMed
Galvin, JE, Pollack, J, Morris, JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006;67:1605–1611.CrossRefGoogle ScholarPubMed
McKeith, IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9:417–423.CrossRefGoogle Scholar
McKeith, IG, Perry, EK, Perry, RH. Report of the Second Dementia with Lewy Body International Workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology. 1999;53:902–905.CrossRefGoogle ScholarPubMed
Baker, M, Mackenzie, IR, Pickering-Brown, SMet al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916–919.CrossRefGoogle ScholarPubMed
Ferman, TJ, Smith, GE, Boeve, BFet al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. Clin Neuropsychol. 2006;20:623–636.CrossRefGoogle ScholarPubMed
Boeve, BF, Silber, MH, Saper, CBet al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130:2770–2778.CrossRefGoogle ScholarPubMed
Boeve, BF, Silber, MH, Ferman, TJet al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology. 1998;51:363–370.CrossRefGoogle ScholarPubMed
Olson, EJ, Boeve, BF, Silber, MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123 (Pt 2):331–339.CrossRefGoogle ScholarPubMed
Boeve, BF, Silber, MH, Ferman, TJet al. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001;16:622–630.CrossRefGoogle ScholarPubMed
Boeve, BF, Silber, MH, Parisi, JEet al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology. 2003;61:40–45.CrossRefGoogle ScholarPubMed
Boeve, B. Dementia with Lewy bodies. In Peterson, R (ed.) Continuum, Vol. 10. Minneapolis: American Academy of Neurology, 2004: 81–112.Google Scholar
Barber, R, Ballard, C, McKeith, IGet al. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology. 2000;54:1304–1309.CrossRefGoogle ScholarPubMed
Burton, EJ, McKeith, IG, Burn, DJet al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain. 2004;127:791–800.CrossRefGoogle ScholarPubMed
Dickson, DW, Crystal, H, Mattiace, et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol (Berl). 1989;78:572–584.CrossRefGoogle ScholarPubMed
Dickson, DW. Dementia with Lewy bodies: neuropathology. J Geriatr Psychiatry Neurol. 2002;15:210–216.CrossRefGoogle ScholarPubMed
Lebert, F, Pasquier, F, Souliez, L, Petit, H. Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry. 1998;13:516–519.3.0.CO;2-O>CrossRefGoogle ScholarPubMed
Querfurth, HW, Allam, GJ, Geffroy, MAet al. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement Geriatr Cogn Disord. 2000;11:314–321.CrossRefGoogle ScholarPubMed
Shea, C, MacKnight, C, Rockwood, K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr. 1998;10:229–238.CrossRefGoogle ScholarPubMed
Lanctot, KL, Herrmann, N. Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry. 2000;15:338–345.3.0.CO;2-U>CrossRefGoogle ScholarPubMed
Samuel, W, Caligiuri, M, Galasko, Det al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000;15:794–802.3.0.CO;2-1>CrossRefGoogle ScholarPubMed
Minett, TS, Thomas, A, Wilkinson, LMet al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18:988–993.CrossRefGoogle ScholarPubMed
McKeith, I, Del Ser, T, Spano, Pet al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031–2036.CrossRefGoogle ScholarPubMed
Grace, JB, Walker, MP, McKeith, IG. A comparison of sleep profiles in patients with dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry. 2000;15:1028–1033.3.0.CO;2-E>CrossRefGoogle ScholarPubMed
Grace, J, Daniel, S, Stevens, Tet al. Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr. 2001;13:199–205.CrossRefGoogle Scholar
Maclean, , Collins, CC, Byrne, EJ. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. Int Psychogeriatr. 2001;13:277–288.CrossRefGoogle ScholarPubMed
Wesnes, KA, McKeith, IG, Ferrara, Ret al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13:183–192.CrossRefGoogle ScholarPubMed
Thomas, AJ, Burn, DJ, Rowan, ENet al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005;20:938–944.CrossRefGoogle ScholarPubMed
Rowan, E, McKeith, IG, Saxby, BKet al. Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2007;23:161–167.CrossRefGoogle ScholarPubMed
Edwards, KR, Hershey, L, Wray, Let al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord. 2004;17(Suppl 1):40–48.CrossRefGoogle ScholarPubMed
Edwards, KR, Royall, D, Hershey, Let al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord. 2007;23:401–405.CrossRefGoogle ScholarPubMed
Walker, Z, Grace, J, Overshot, Ret al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry. 1999;14:459–466.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Cummings, JL, Street, J, Masterman, D, Clark, WS. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2002;13:67–73.CrossRefGoogle ScholarPubMed
Fernandez, HH, Trieschmann, ME, Burke, MA, Friedman, JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002;63:513–515.CrossRefGoogle ScholarPubMed
Takahashi, H, Yoshida, K, Sugita, Tet al. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:549–553.CrossRefGoogle ScholarPubMed
Bonelli, SB, Ransmayr, G, Steffelbauer, Met al. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology. 2004;63:376–378.CrossRefGoogle ScholarPubMed
Molloy, S, McKeith, IG, O'Brien, JT, Burn, DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76:1200–1203.CrossRefGoogle ScholarPubMed
Courtney, C, Farrell, D, Gray, Ret al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105–2115.Google ScholarPubMed
Ballard, CG, Chalmers, KA, Todd, Cet al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology. 2007;68:1726–1729.CrossRefGoogle ScholarPubMed
Pakrasi, S, Thomas, A, Mosimann, UPet al. Cholinesterase inhibitors in advanced dementia with Lewy bodies: increase or stop?Int J Geriatr Psychiatry. 2006;21:719–721.CrossRefGoogle ScholarPubMed
Molloy, SA, Rowan, EN, O'Brien, JTet al. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77:1323–1328.CrossRefGoogle ScholarPubMed
Miyasaki, JM, Shannon, K, Voon, Vet al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996–1002.CrossRefGoogle ScholarPubMed
Bhanji, NH, Gauthier, S. Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 2005;17:552–555.CrossRefGoogle ScholarPubMed
Ridha, BH, Josephs, KA, Rossor, MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology. 2005;65:481–482.CrossRefGoogle ScholarPubMed
Sabbagh, MN, Hake, AM, Ahmed, S, Farlow, MR. The use of memantine in dementia with Lewy bodies. J Alzheimers Dis. 2005;7:285–289.CrossRefGoogle ScholarPubMed
McKeith, I, Fairbairn, A, Perry, Ret al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305:673–678.CrossRefGoogle ScholarPubMed
Kurlan, R, Cummings, J, Raman, R, Thal, L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356–1363.CrossRefGoogle ScholarPubMed
Hutchinson, M, Fazzini, E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996;61:324–325.CrossRefGoogle ScholarPubMed
Werber, EA, Rabey, JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm. 2001;108:1319–1325.CrossRefGoogle ScholarPubMed
Fabbrini, G, Barbanti, P, Aurilia, Cet al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci. 2002;23:41–43.CrossRefGoogle ScholarPubMed
Bergman, J, Lerner, V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 2002;25:107–110.CrossRefGoogle ScholarPubMed
Aarsland, D, Laake, K, Larsen, JP, Janvin, C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72:708–712.CrossRefGoogle ScholarPubMed
Leroi, I, Brandt, J, Reich, SGet al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004;19:1–8.CrossRefGoogle ScholarPubMed
Ravina, B, Putt, M, Siderowf, Aet al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76:934–939.CrossRefGoogle ScholarPubMed
Reading, PJ, Luce, AK, McKeith, IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16:1171–1174.CrossRefGoogle ScholarPubMed
Bullock, R, Cameron, A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002;18:258–264.CrossRefGoogle ScholarPubMed
Giladi, N, Shabtai, H, Gurevich, Tet al. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand. 2003;108:368–373.CrossRefGoogle ScholarPubMed
Emre, M, Aarsland, D, Albanese, Aet al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509–2518.CrossRefGoogle ScholarPubMed
Aarsland, D, Hutchinson, M, Larsen, JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18:937–941.CrossRefGoogle ScholarPubMed
Ostergaard, K, Dupont, E. Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson's disease. Acta Neurol Scand. 1988; 78:349–350.CrossRefGoogle ScholarPubMed
Friedman, JH, Lannon, MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology. 1989;39:1219–1221.CrossRefGoogle ScholarPubMed
Pfeiffer, RF, Kang, J, Graber, Bet al. Clozapine for psychosis in Parkinson's disease. Mov Disord. 1990;5:239–242.CrossRefGoogle ScholarPubMed
Wolters, EC, Hurwitz, TA, Mak, Eet al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990;40:832–834.CrossRefGoogle ScholarPubMed
Kahn, N, Freeman, A, Juncos, JLet al. Clozapine is beneficial for psychosis in Parkinson's disease. Neurology. 1991;41:1699–1700.CrossRefGoogle ScholarPubMed
Wolk, SI, Douglas, CJ. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. J Clin Psychiatry. 1992;53:373–376.Google ScholarPubMed
Greene, P, Cote, L, Fahn, S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol. 1993;60:703–706.Google ScholarPubMed
Factor, SA, Brown, D, Molho, ES, Podskalny, GD. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology. 1994;44:544–546.CrossRefGoogle ScholarPubMed
Chacko, RC, Hurley, RA, Harper, RGet al. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995;7:471–475.Google ScholarPubMed
Rabey, JM, Treves, TA, Neufeld, MYet al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology. 1995;45:432–434.CrossRefGoogle ScholarPubMed
Rich, SS, Friedman, JH, Ott, BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995;56:556–559.Google ScholarPubMed
Wagner, ML, Defilippi, JL, Menza, MA, Sage, JI. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci. 1996;8:276–280.Google ScholarPubMed
Bonuccelli, U, Ceravolo, R, Salvetti, Set al. Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration. Neurology. 1997;49:1587–1590.CrossRefGoogle ScholarPubMed
Ruggieri, S, Pandis, MF, Bonamartini, Aet al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol. 1997;20:204–209.CrossRefGoogle ScholarPubMed
Widman, LP, Burke, WJ, Pfeiffer, RF, McArthur-Campbell, D. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review. J Geriatr Psychiatry Neurol. 1997;10:63–66.CrossRefGoogle ScholarPubMed
Friedman, JH, Goldstein, S, Jacques, C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998;21:285–288.Google ScholarPubMed
Pierelli, F, Adipietro, A, Soldati, Get al. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand. 1998;97:295–299.CrossRefGoogle ScholarPubMed
Trosch, RM, Friedman, JH, Lannon, MCet al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord. 1998;13:377–382.CrossRefGoogle ScholarPubMed
,The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999;353:2041–2042.
Dewey, RB, O'Suilleabhain, PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology. 2000;55:1753–1754.CrossRefGoogle ScholarPubMed
Goetz, CG, Blasucci, LM, Leurgans, S, Pappert, EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000;55:789–794.CrossRefGoogle ScholarPubMed
Ellis, T, Cudkowicz, ME, Sexton, PM, Growdon, JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2000;12:364–369.CrossRefGoogle ScholarPubMed
Factor, SA, Friedman, JH, Lannon, MCet al. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001;16:135–139.3.0.CO;2-Q>CrossRefGoogle ScholarPubMed
Morgante, L, Epifanio, A, Spina, Eet al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci. 2002;23(Suppl 2): S89–S90.CrossRefGoogle ScholarPubMed
Morgante, L, Epifanio, A, Spina, Eet al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153–156.CrossRefGoogle ScholarPubMed
Fernandez, HH, Friedman, JH, Jacques, C, Rosenfeld, M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 1999;14:484–487.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
Targum, SD, Abbott, JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol. 2000;20:54–60.CrossRefGoogle ScholarPubMed
Reddy, S, Factor, SA, Molho, ES, Feustel, PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord. 2002;17:676–681.CrossRefGoogle ScholarPubMed
Baron, MS, Dalton, WB. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease. Mov Disord. 2003;18:1208–1209.CrossRefGoogle ScholarPubMed
Fernandez, HH, Trieschmann, ME, Burke, MAet al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003;18:510–514.CrossRefGoogle ScholarPubMed
Gimenez-Roldan, S, Navarro, E, Mateo, D. [Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease.] Rev Neurol. 2003;36:401–404.Google ScholarPubMed
Katzenschlager, R, Manson, AJ, Evans, Aet al. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry. 2004;75:295–297.Google ScholarPubMed
Juncos, JL, Roberts, VJ, Evatt, MLet al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord. 2004;19:29–35.CrossRefGoogle ScholarPubMed
Mancini, F, Tassorelli, C, Martignoni, Eet al. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. Clin Neuropharmacol. 2004;27:33–37.CrossRefGoogle ScholarPubMed
Rabey, JM, Prokhorov, T, Miniovitz, A, Dobronevsky, Eet al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2007;22:313–318.CrossRefGoogle ScholarPubMed
Meco, G, Alessandri, A, Giustini, P, Bonifati, V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord. 1997;12:610–612.CrossRefGoogle Scholar
Workman, RH, Orengo, CA, Bakey, AAet al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1997;9:594–597.Google ScholarPubMed
Leopold, NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord. 2000;15:301–304.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
Mohr, E, Mendis, T, Hildebrand, K, Deyn, PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord. 2000;15:1230–1237.3.0.CO;2-9>CrossRefGoogle Scholar
Graham, JM, Sussman, JD, Ford, KS, Sagar, HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry. 1998;65:774–777.CrossRefGoogle ScholarPubMed
Aarsland, D, Larsen, JP, Lim, NG, Tandberg, E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci. 1999;11:392–394.CrossRefGoogle ScholarPubMed
Molho, ES, Factor, SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord. 1999;14:1014–1016.3.0.CO;2-9>CrossRefGoogle ScholarPubMed
Brier, A, Sutton, VK, Feldman, PDet al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002;52:438–445.CrossRefGoogle Scholar
Marsh, L, Lyketsos, C, Reich, SG. Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics. 2001;42:477–481.CrossRefGoogle ScholarPubMed
Ondo, WG, Levy, JK, Vuong, KDet al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031–1035.CrossRefGoogle ScholarPubMed
Fernandez, HH, Trieschmann, ME, Friedman, JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004;27:4–5.CrossRefGoogle ScholarPubMed
Rasmussen, KG, Russell, JC, Kung, Set al. Electroconvulsive therapy for patients with major depression and probable Lewy body dementia. J ECT. 2003;19:103–109.CrossRefGoogle ScholarPubMed
Thaisetthawatkul, P, Boeve, BF, Benarroch, EEet al. Autonomic dysfunction in dementia with Lewy bodies. Neurology. 2004;62:1804–1809.CrossRefGoogle ScholarPubMed
Benarroch, EE, Schmeichel, AM, Low, PAet al. Involvement of medullary regions controlling sympathetic output in Lewy body disease. Brain. 2005;128:338–344.CrossRefGoogle ScholarPubMed
Allan, LM, Ballard, CG, Allen, Jet al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry. 2007;78:671–677.CrossRefGoogle ScholarPubMed
Boeve, BF, Silber, MH, Ferman, TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4:281–284.CrossRefGoogle ScholarPubMed
Boeve, BF, Silber, MH, Ferman, TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17:146–157.CrossRefGoogle ScholarPubMed
Massironi, G, Galluzzi, S, Frisoni, GB. Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr. 2003;15:377–383.CrossRefGoogle ScholarPubMed
McKeith, I, Mintzer, J, Aarsland, Det al. Dementia with Lewy bodies. Lancet Neurol. 2004;3:19–28.CrossRefGoogle ScholarPubMed
Aarsland, D, Andersen, K, Larsen, JPet al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387–392.CrossRefGoogle Scholar
Lippa, CF, Duda, JE, Grossman, Met al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812–819.CrossRefGoogle ScholarPubMed
Wesnes, KA, McKeith, I, Edgar, Cet al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65:1654–1656.CrossRefGoogle ScholarPubMed
Muller, T, Welnic, J, Fuchs, Get al. The DONPAD-study: treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl. 2006:27–30.CrossRefGoogle ScholarPubMed
Burn, D, Emre, M, McKeith, Iet al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord. 2006;21:1899–1907.CrossRefGoogle ScholarPubMed
Poewe, W, Wolters, E, Emre, Met al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord. 2006;21:456–461.CrossRefGoogle ScholarPubMed
,The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340:757–763.CrossRefGoogle Scholar
Fernandez, HH, Lannon, MC, Friedman, JH, Abbott, BP. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000;15:579–581.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Aarsland, D, Larsen, JP, Karlsen, Ket al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry. 1999;14:866–874.3.0.CO;2-Z>CrossRefGoogle ScholarPubMed
Ananth, H, Popescu, I, Critchley, HDet al. Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry. 2002;159:1497–1505.CrossRefGoogle ScholarPubMed
Chui, HC, Mack, W, Jackson, JEet al. Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol. 2000;57:191–196.CrossRefGoogle Scholar
Erkinjuntti, T, Inzitari, D, Pantoni, Let al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000;59:23–30.Google ScholarPubMed
Forette, F, Seux, ML, Staessen, JAet al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347–1351.CrossRefGoogle ScholarPubMed
Forette, F, Seux, ML, Staessen, JAet al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046–2052.CrossRefGoogle ScholarPubMed
Tzourio, C, Anderson, C, Chapman, Net al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069–1075.Google ScholarPubMed
Feigin, V, Ratnasabapathy, Y, Anderson, C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease?J Neurol Sci. 2005;229–230:151–155.CrossRefGoogle Scholar
Meyer, JS, Chowdhury, MH, Xu, Get al. Donepezil treatment of vascular dementia. Ann N Y Acad Sci. 2002;977:482–486.CrossRefGoogle ScholarPubMed
Black, S, Roman, GC, Geldmacher, DSet al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323–2330.CrossRefGoogle ScholarPubMed
Wilkinson, D, Doody, R, Helme, Ret al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479–486.CrossRefGoogle ScholarPubMed
Moretti, R, Torre, P, Antonello, RM, Cazzato, G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol. 2001;8:361–362.CrossRefGoogle ScholarPubMed
Moretti, R, Torre, P, Antonello, RMet al. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci. 2002;203–204:141–146.CrossRefGoogle ScholarPubMed
Kumar, V, Anand, R, Messina, Jet al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000;7:159–169.CrossRefGoogle ScholarPubMed
Moretti, R, Torre, P, Antonello, RMet al. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. Am J Alzheimers Dis Other Demen. 2003;18:265–272.CrossRefGoogle ScholarPubMed
Moretti, R, Torre, P, Antonello, RMet al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931–937.CrossRefGoogle Scholar
Erkinjuntti, T, Kurz, A, Gauthier, Set al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283–1290.CrossRefGoogle ScholarPubMed
Erkinjuntti, T, Kurz, A, Small, GWet al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther. 2003;25:1765–1782.CrossRefGoogle ScholarPubMed
Orgogozo, JM, Rigaud, AS, Stoffler, Aet al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834–1839.CrossRefGoogle Scholar
Wilcock, G, Mobius, HJ, Stoffler, A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297–305.CrossRefGoogle Scholar
Meyer, JS, Rogers, RL, McClintic, Ket al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989;37:549–555.CrossRefGoogle ScholarPubMed
Devine, ME, Rands, G. Does aspirin affect outcome in vascular dementia? A retrospective case-notes analysis. Int J Geriatr Psychiatry. 2003;18:425–431.CrossRefGoogle ScholarPubMed
Olin, J, Schneider, L, Novit, A, Luczak, S. Hydergine for dementia. Cochrane Database Syst Rev. 2000; 1: CD000359.Google Scholar
Ghose, K. Oxpentifylline in dementia: a controlled study. Arch Gerontol Geriatr. 1987;6:19–26.CrossRefGoogle ScholarPubMed
Black, RS, Barclay, LL, Nolan, KAet al. Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc. 1992;40:237–244.CrossRefGoogle ScholarPubMed
Blume, J, Ruhlmann, KU, Haye, R, Rettig, K. Treatment of chronic cerebrovascular disease in elderly patients with pentoxifylline. J Med. 1992;23:417–432.Google ScholarPubMed
,European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol. 1996;36:315–321.
Marcusson, J, Rother, M, Kittner, Bet al. A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement Geriatr Cogn Disord. 1997;8:320–328.CrossRefGoogle ScholarPubMed
Parnetti, L, Ambrosoli, L, Agliati, Get al. Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs placebo. Acta Neurol Scand. 1996;93:456–463.CrossRefGoogle ScholarPubMed
Herrmann, WM, Stephan, K, Gaede, K, Apeceche, M. A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord. 1997;8:9–17.CrossRefGoogle ScholarPubMed
Pantoni, L, Carosi, M, Amigoni, Set al. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol. 1996;19:497–506.CrossRefGoogle ScholarPubMed
Pantoni, L, del Ser, T, Soglian, AGet al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke. 2005;36:619–624.CrossRefGoogle ScholarPubMed
Brodaty, H, Ames, D, Snowdon, Jet al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134–143.CrossRefGoogle Scholar
Bars, PL, Kieser, M, Itil, KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord. 2000;11:230–237.CrossRefGoogle ScholarPubMed
Kanowski, S, Hoerr, R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry. 2003;36:297–303.Google ScholarPubMed
Moretti, R, Torre, P, Antonello, RMet al. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. Int J Clin Pract. 2004;58:346–353.CrossRefGoogle ScholarPubMed
Schneider, LS, Olin, JT. Overview of clinical trials of hydergine in dementia. Arch Neurol. 1994;51:787–798.CrossRefGoogle Scholar
Pantoni, L, Bianchi, C, Beneke, Met al. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 2000;175:116–123.CrossRefGoogle ScholarPubMed
Pantoni, L, Rossi, R, Inzitari, Det al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci. 2000;175:124–134.CrossRefGoogle ScholarPubMed
Cohen, RA, Browndyke, JN, Moser, DJet al. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes. Cerebrovasc Dis. 2003;16:199–204.CrossRefGoogle ScholarPubMed
Demaerschalk, BM, Wingerchuk, DM. Treatment of vascular dementia and vascular cognitive impairment. Neurologist. 2007;13:37–41.CrossRefGoogle ScholarPubMed
Neary, D, Snowden, JS, Gustafson, Let al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–1554.CrossRefGoogle ScholarPubMed
Forman, MS, Farmer, J, Johnson, JKet al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952–962.CrossRefGoogle ScholarPubMed
Josephs, KA, Petersen, RC, Knopman, DSet al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66:41–48.CrossRefGoogle ScholarPubMed
Neumann, M, Sampathu, DM, Kwong, LKet al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133.CrossRefGoogle ScholarPubMed
Wszolek, ZK, Tsuboi, Y, Farrer, Met al. Hereditary tauopathies and parkinsonism. Adv Neurol. 2003;91:153–163.Google ScholarPubMed
Vance, C, Al-Chalabi, A, Ruddy, Det al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2–21.3. Brain. 2006;129:868–876.CrossRefGoogle ScholarPubMed
Morita, M, Al-Chalabi, A, Andersen, PMet al. A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology. 2006;66:839–844.CrossRefGoogle ScholarPubMed
Cannon, A, Baker, M, Boeve, Bet al. CHMP2B mutations are not a common cause of frontotemporal lobar degeneration. Neurosci Lett. 2006;398:83–84.CrossRefGoogle Scholar
Cruts, M, Gijselinck, I, Zee, Jet al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920–924.CrossRefGoogle ScholarPubMed
Spina, S, Murrell, JR, Huey, EDet al. Clinicopathologic features of frontotemporal dementia with progranulin sequence variation. Neurology. 2007;68:820–827.CrossRefGoogle ScholarPubMed
Boeve, BF, Baker, M, Dickson, DWet al. Frontotemporal dementia and parkinsonism associated with the IVS1+1G→A mutation in progranulin: a clinicopathologic study. Brain. 2006;129:3103–3114.CrossRefGoogle ScholarPubMed
Mesulam, M, Johnson, N, Krefft, TAet al. Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. Arch Neurol. 2007;64:43–47.CrossRefGoogle Scholar
Mukherjee, O, Pastor, P, Cairns, NJet al. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol. 2006;60:314–322.CrossRefGoogle ScholarPubMed
Behrens, MI, Mukherjee, O, Tu, PHet al. Neuropathologic heterogeneity in HDDD1: a familial frontotemporal lobar degeneration with ubiquitin-positive inclusions and progranulin mutation. Alzheimer Dis Assoc Disord. 2007;21:1–7.CrossRefGoogle ScholarPubMed
Cairns, NJ, Neumann, M, Bigio, EHet al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171(1):227–240.CrossRefGoogle ScholarPubMed
,The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57:416–418.CrossRef
Miller, BL, Chang, L, Mena, Iet al. Progressive right frontotemporal degeneration: clinical, neuropsychological and SPECT characteristics. Dementia. 1993;4:204–213.Google ScholarPubMed
Miller, BL, Cummings, J, Mishkin, Fet al. Emergence of artistic talent in frontotemporal dementia. Neurology. 1998;51:978–982.CrossRefGoogle ScholarPubMed
Swartz, JR, Miller, BL, Lesser, IM, Darby, AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212–216.CrossRefGoogle ScholarPubMed
Deakin, JB, Rahman, S, Nestor, PJet al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172:400–408.Google Scholar
Lebert, F, Stekke, W, Hasenbroekx, C, Pasquier, F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355–359.CrossRefGoogle ScholarPubMed
Mendez, MF, Shapira, JS, McMurtray, A, Licht, E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84–87.CrossRefGoogle ScholarPubMed
Huey, ED, Putnam, KT, Grafman, J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17–22.CrossRefGoogle ScholarPubMed
Moretti, R, Torre, P, Antonello, RMet al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13–19.CrossRefGoogle ScholarPubMed
Noble, W, Planel, E, Zehr, Cet al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990–6995.CrossRefGoogle ScholarPubMed
Dickey, CA, Yue, M, Lin, WLet al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci. 2006;26:6985–6996.CrossRefGoogle Scholar
Dickey, CA, Kamal, A, Lundgren, Ket al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest. 2007;117:648–658.CrossRefGoogle ScholarPubMed
Mesulam, M. Primary progressive aphasia without generalized dementia. Ann Neurol. 1982;11:592–598.CrossRefGoogle Scholar
Duffy, JR PR. Primary progressive aphasia. Aphasiology. 1992;6:1–15.CrossRefGoogle Scholar
Damasio, A. Disorders of complex visual processing: agnosias, achromatopsia, Balint's syndrome, and related difficulties of orientation and construction. In Mesulam, M-M (ed.) Principles of Behavioral Neurology. Philadelphia, PA: F. A. Davis, 1985:259–288.Google Scholar
Evans, JJ, Heggs, AJ, Antoun, N, Hodges, JR. Progressive prosopagnosia associated with selective right temporal lobe atrophy. A new syndrome? Brain. 1995;118:1–13.Google ScholarPubMed
Reed, DA, Johnson, NA, Thompson, Cet al. A clinical trial of bromocriptine for treatment of primary progressive aphasia. Ann Neurol. 2004;56:750.CrossRefGoogle ScholarPubMed
Berthier, ML. Poststroke aphasia: epidemiology, pathophysiology and treatment. Drugs Aging. 2005;22:163–182.CrossRefGoogle ScholarPubMed
Rebeiz, JJ, Kolodny, EH, Richardson, EP. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc. 1967;92:23–26.Google ScholarPubMed
MaraganoreDM, Ahlskog JE DM, Ahlskog JE, Petersen, RC. Progressive asymmetric rigidity with apraxia: a distinctive clinical entity (abstract). Mov Disord. 1992;7(Suppl 1):80.Google Scholar
Lang, AERD, Bergeron, C. Cortical-basal ganglionic degeneration. In Calne, DB (ed.) Neurodegenerative Diseases. Philadelphia, PA: WB Saunders, 1994:877–894.Google Scholar
Kumar, RBC, Pollanen, MS, Lang, AE. Cortical-basal ganglionic degeneration. In Jankovic, JTE (ed.) Parkinson's Disease and Movement Disorders. 3rd edn. Baltimore, MD: Williams & Wilkins, 1998: 297–316.Google Scholar
Kompoliti, K, Goetz, CG, Litvan, Iet al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998;55:1099–1102.CrossRefGoogle ScholarPubMed
GedaY, Boeve B Y, Boeve B, Parisi, Jet al. Neuropsychiatric features in 20 cases of pathologically-confirmed corticobasal degeneration. Mov Disord. 2000;15(Suppl 3):229.Google Scholar
Grimes, DA, Lang, AE, Bergeron, CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology. 1999;53:1969–1974.CrossRefGoogle ScholarPubMed
Boeve, B. Corticobasal degeneration: the syndrome and the disease. In Litvan, I (ed.) Atypical Parkinsonian Disorders. Totowa, NJ: Humana Press, 2005:309–334.CrossRefGoogle Scholar
Kompoliti, K, Goetz, CG, Boeve, BFet al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998;55:957–961.CrossRefGoogle ScholarPubMed
Boeve, BF, Maraganore, DM, Parisi, JEet al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology. 1999;53:795–800.CrossRefGoogle ScholarPubMed
Josephs, KA, Holton, JL, Rossor, MNet al. Neurofilament inclusion body disease: a new proteinopathy?Brain. 2003;126:2291–2303.CrossRefGoogle ScholarPubMed
Boeve, BF, Lang, AE, Litvan, I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol. 2003;54(Suppl 5):S15–S19.CrossRefGoogle ScholarPubMed
Steele, JC, Richardson, JC, Olszewski, J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10:333–359.CrossRefGoogle ScholarPubMed
Litvan, I, Agid, Y, Calne, Det al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS–SPSP International Workshop. Neurology. 1996;47:1–9.CrossRefGoogle Scholar
Litvan, I, Mega, MS, Cummings, JL, Fairbanks, L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996;47:1184–1189.CrossRefGoogle ScholarPubMed
RipponG, Boeve B G, Boeve B, Parisi, J, Dickson, Det al. Atypical progressive supranuclear palsy presenting as frontotemporal dementia. Neurocase. 2005;11:1–8.Google Scholar
Nieforth, KA, Golbe, LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16:338–346.CrossRefGoogle ScholarPubMed
Cole, DG, Growdon, JH. Therapy for progressive supranuclear palsy: past and future. J Neural Transm Suppl. 1994;42:283–290.CrossRefGoogle ScholarPubMed
Fabbrini, G, Barbanti, P, Bonifati, Vet al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103:123–125.CrossRefGoogle ScholarPubMed
Litvan, I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol. 2001;21:41–48.CrossRefGoogle ScholarPubMed
Frattali, CM, Sonies, BC, Chi-Fishman, G, Litvan, I. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: a pilot study. Dysphagia. 1999;14:165–168.CrossRefGoogle ScholarPubMed
Rascol, O, Sieradzan, K, Peyro-Saint-Paul, Het al. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov Disord. 1998;13:673–676.CrossRefGoogle ScholarPubMed
Weiner, WJ, Minagar, A, Shulman, LM. Pramipexole in progressive supranuclear palsy. Neurology. 1999;52:873–874.CrossRefGoogle ScholarPubMed
,Human transmissible spongiform encephalopathies. Wkly Epidemiol Rec. 1998;73:361–365.
Collinge, J. New diagnostic tests for prion diseases. N Engl J Med. 1996;335:963–965.Google ScholarPubMed
Korth, C, May, BC, Cohen, FE, Prusiner, SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA. 2001;98:9836–9841.CrossRefGoogle ScholarPubMed
Nakajima, M, Yamada, T, Kusuhara, Tet al. Results of quinacrine administration to patients with Creutzfeldt–Jakob disease. Dement Geriatr Cogn Disord. 2004;17:158–163.CrossRefGoogle ScholarPubMed
Otto, M, Cepek, L, Ratzka, Pet al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology. 2004;62:714–718.CrossRefGoogle ScholarPubMed
Haïk, S, Brandel, JP, Salomon, Det al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004;63:2413–2415.CrossRefGoogle ScholarPubMed
Ironside, JW. Neuropathological findings in new variant CJD and experimental transmission of BSE. FEMS Immunol Med Microbiol. 1998;21:91–95.CrossRefGoogle ScholarPubMed
Scott, MR, Will, R, Ironside, Jet al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci USA. 1999;96:15137–15142.CrossRefGoogle Scholar
Zeidler, M, Johnstone, EC, Bamber, RWet al. New variant Creutzfeldt–Jakob disease: psychiatric features. Lancet. 1997;350:908–910.CrossRefGoogle ScholarPubMed
Zeidler, M, Stewart, GE, Barraclough, CRet al. New variant Creutzfeldt–Jakob disease: neurological features and diagnostic tests. Lancet. 1997;350:903–907.CrossRefGoogle ScholarPubMed
Will, RG, Zeidler, M, Stewart, GEet al. Diagnosis of new variant Creutzfeldt–Jakob disease. Ann Neurol. 2000;47:575–582.3.0.CO;2-W>CrossRefGoogle ScholarPubMed
Coulthard, A, Hall, K, English, PTet al. Quantitative analysis of MRI signal intensity in new variant Creutzfeldt–Jakob disease. Br J Radiol. 1999;72:742–748.Google ScholarPubMed
Carlson, DL, Fleming, KC, Smith, GE, Evans, JM. Management of dementia-related behavioral disturbances: a nonpharmacologic approach. Mayo Clin Proc. 1995;70:1108–1115.CrossRefGoogle ScholarPubMed
Knopman, DS, Sawyer-DeMaris, S. Practical approach to managing behavioral problems in dementia patients. Geriatrics. 1990;45:27–30, 35.Google ScholarPubMed
Boeve, BF, Silber, MH, Ferman, TJ. Current management of sleep disturbances in dementia. Curr Neurol Neurosci Rep. 2002;2:169–177.CrossRefGoogle ScholarPubMed
Tariot, PN, Profenno, , Ismail, MS. Efficacy of atypical antipsychotics in elderly patients with dementia. J Clin Psychiatry. 2004;65(Suppl 11):11–15.Google ScholarPubMed
Sink, KM, Holden, KF, Yaffe, K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596–608.CrossRefGoogle Scholar
McKeith, IG, Grace, JB, Walker, Zet al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry. 2000;15:387–392.3.0.CO;2-9>CrossRefGoogle ScholarPubMed
Saykin, AJ, Wishart, HA, Rabin, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain. 2004;127:1574–1583.CrossRefGoogle Scholar
Finkel, SI. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J Clin Psychiatry. 2001;62(Suppl 21):3–6.Google ScholarPubMed
Beeri, MS, Werner, P, Davidson, M, Noy, S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry. 2002;17:403–408.CrossRefGoogle Scholar
Stotsky, B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin Ther. 1984;6:546–559.Google ScholarPubMed
Schneider, LS, Pollock, VE, Lyness, SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38:553–563.Google ScholarPubMed
Lonergan, E, Luxenberg, J, Colford, J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;4:CD002852.Google Scholar
Pollock, BG, Mulsant, BH, Rosen, Jet al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460–465.CrossRefGoogle ScholarPubMed
Deyn, PP, Rabheru, K, Rasmussen, Aet al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946–955.CrossRefGoogle ScholarPubMed
Katz, IR, Jeste, DV, Mintzer, JEet al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107–115.CrossRefGoogle ScholarPubMed
Street, JS, Clark, WS, Gannon, KSet al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968–976.CrossRefGoogle ScholarPubMed
Meehan, KM, Wang, H, David, SRet al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26:494–504.CrossRefGoogle ScholarPubMed
Deyn, PP, Carrasco, MM, Deberdt, Wet al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:115–126.CrossRefGoogle ScholarPubMed
Tariot, PN, Salzman, C, Yeung, PPet al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000;22:1068–1084.CrossRefGoogle ScholarPubMed
Feldman, H, Gauthier, S, Hecker, Jet al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613–620.Google ScholarPubMed
Holmes, C, Wilkinson, D, Dean, Cet al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63:214–219.CrossRefGoogle ScholarPubMed
Gauthier, S, Wirth, Y, Mobius, HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry. 2005;20:459–464.CrossRefGoogle ScholarPubMed
Auchus, AP, Bissey-Black, C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1997;9:591–593.Google ScholarPubMed
Lyketsos, CG, DelCampo, L, Steinberg, Met al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–746.CrossRefGoogle ScholarPubMed
Finkel, SI, Mintzer, JE, Dysken, Met al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19:9–18.CrossRefGoogle ScholarPubMed
Teri, L, Logsdon, RG, Peskind, Eet al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55:1271–1278.CrossRefGoogle ScholarPubMed
Tariot, PN, Erb, R, Podgorski, CAet al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54–61.CrossRefGoogle ScholarPubMed
Olin, JT, Fox, LS, Pawluczyk, Set al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9:400–405.CrossRefGoogle ScholarPubMed
Porsteinsson, AP, Tariot, PN, Erb, Ret al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001;9:58–66.CrossRefGoogle ScholarPubMed
Sival, RC, Haffmans, PM, Jansen, PAet al. Sodium valproate in the treatment of aggressive behavior in patients with dementia–a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry. 2002;17:579–585.CrossRefGoogle ScholarPubMed
Schneider, LS, Tariot, PN, Dagerman, KSet al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525–1538.CrossRefGoogle ScholarPubMed
Tariot, PN, Schneider, L, Katz, IRet al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14:767–776.CrossRefGoogle ScholarPubMed
Deyn, P, Jeste, DV, Swanink, Ret al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25:463–467.CrossRefGoogle ScholarPubMed
Tariot, PN, Cummings, JL, Katz, IRet al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590–1599.CrossRefGoogle ScholarPubMed
Olin, J, Schneider, L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747.Google ScholarPubMed
Reisberg, B, Doody, R, Stöffler, Aet al. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333–1341.CrossRefGoogle Scholar
MedWatch, F. Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. Rockville, MD: US Food and Drug Administration, 2003, 2005.Google Scholar
MedWatch, F. Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements. Rockville, MD: US Food and Drug Administration, 2004.Google Scholar
,Research FCfDEa. FDA Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Rockville, MD: US Food and Drug Administration, 2005.
Schneider, LS, Dagerman, KS, Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–1943.CrossRefGoogle ScholarPubMed
Marin, RS, Fogel, BS, Hawkins, Jet al. Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci. 1995;7:23–30.Google ScholarPubMed
Reekum, R, Stuss, DT, Ostrander, L. Apathy: why care?J Neuropsychiatry Clin Neurosci. 2005;17:7–19.CrossRefGoogle ScholarPubMed
MacKnight, C, Rojas-Fernandez, C. Quetiapine for sexually inappropriate behavior in dementia. J Am Geriatr Soc. 2000;48:707.CrossRefGoogle ScholarPubMed
Stewart, JT, Shin, KJ. Paroxetine treatment of sexual disinhibition in dementia. Am J Psychiatry. 1997;154:1474.Google ScholarPubMed
Leo, RJ, Kim, KY. Clomipramine treatment of paraphilias in elderly demented patients. J Geriatr Psychiatry Neurol. 1995;8:123–124.CrossRefGoogle Scholar
Tiller, JW, Dakis, JA, Shaw, JM. Short-term buspirone treatment in disinhibition with dementia. Lancet. 1988;2:510.Google ScholarPubMed
Lopez, OL, Jagust, WJ, Dulberg, Cet al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol. 2003;60:1394–1399.CrossRefGoogle ScholarPubMed
Lauterbach, EC, Schweri, MM. Amelioration of pseudobulbar affect by fluoxetine: possible alteration of dopamine-related pathophysiology by a selective serotonin reuptake inhibitor. J Clin Psychopharmacol. 1991;11:392–393.CrossRefGoogle ScholarPubMed
Messiha, FS. Fluoxetine: a spectrum of clinical applications and postulates of underlying mechanisms. Neurosci Biobehav Rev. 1993;17:385–396.CrossRefGoogle ScholarPubMed
Shader, RI.Does lithium both cause and treat pseudobulbar affect?J Clin Psychopharmacol. 1992;12:360.Google ScholarPubMed
Seliger, GM, Hornstein, A. Serotonin, fluoxetine, and pseudobulbar affect. Neurology. 1989;39:1400.CrossRefGoogle ScholarPubMed
Brooks, BR, Thisted, RA, Appel, SHet al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63:1364–1370.CrossRefGoogle ScholarPubMed
Rosen, HJ, Cummings, J. A real reason for patients with pseudobulbar affect to smile. Ann Neurol. 2007;61:92–96.CrossRefGoogle ScholarPubMed
Skelly, J, Flint, AJ. Urinary incontinence associated with dementia. J Am Geriatr Soc. 1995;43:286–294.CrossRefGoogle ScholarPubMed
Kay, GG, Abou-Donia, MB, Messer, WSet al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53:2195–2201.CrossRefGoogle ScholarPubMed
Ouslander, JG, Zarit, SH, Orr, NK, Muira, SA. Incontinence among elderly community-dwelling dementia patients. Characteristics, management, and impact on caregivers. J Am Geriatr Soc. 1990;38:440–445.CrossRefGoogle ScholarPubMed
Ouslander, JG, Uman, GC, Urman, HN, Rubenstein, LZ. Incontinence among nursing home patients: clinical and functional correlates. J Am Geriatr Soc. 1987;35:324–330.CrossRefGoogle ScholarPubMed
Mishima, K, Okawa, M, Hozumi, S, Hishikawa, Y. Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int. 2000;17:419–432.CrossRefGoogle ScholarPubMed
Asplund, R. Sleep disorders in the elderly. Drugs Aging. 1999;14:91–103.CrossRefGoogle Scholar
Brusco, LI, Fainstein, I, Marquez, M, Cardinali, DP. Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept. 1999;8:126–131.CrossRefGoogle ScholarPubMed
Campbell, SS, Terman, M, Lewy, AJet al. Light treatment for sleep disorders: consensus report. V. Age-related disturbances. J Biol Rhythms. 1995;10:151–154.CrossRefGoogle ScholarPubMed
Gerner, RH. Geriatric depression and treatment with trazodone. Psychopathology. 1987;20 Suppl 1:82–91.CrossRefGoogle ScholarPubMed
Gurian, B, Rosowsky, E. Low-dose methylphenidate in the very old. J Geriatr Psychiatry Neurol. 1990;3:152–154.Google ScholarPubMed
Schenck, CH, Mahowald, MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep. 2002;25:120–138.CrossRefGoogle ScholarPubMed
Vitiello, MV, Bliwise, DL, Prinz, PN. Sleep in Alzheimer's disease and the sundown syndrome. Neurology. 1992;42:83–93; discussion 93–84.Google ScholarPubMed
Bliwise, DL, Carroll, JS, Lee, KAet al. Sleep and “sundowning” in nursing home patients with dementia. Psychiatry Res. 1993;48:277–292.CrossRefGoogle ScholarPubMed
McGaffigan, S, Bliwise, DL. The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies. Drugs Aging. 1997;10:10–17.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×